On October 15, 2020 Genmab A/S (Nasdaq: GMAB) reported that it will hold a Capital Markets Day for analysts and investors on November 13, 2020 from 8:30 AM EST / 2:30 PM CET to 11:00 AM EST / 5:00 PM CET (Press release, Genmab, OCT 15, 2020, View Source [SID1234568517]). The event will be webcast live from Genmab’s state-of-the-art R&D Center in Utrecht, the Netherlands, and from its new offices and laboratory facilities in Princeton, NJ, US. The Capital Markets Day will feature Genmab’s Executive Management Team and a variety of high-level Genmab speakers who will provide updates on Genmab’s business and the ways in which we are delivering on our commitments and evolving into a fully integrated biotech innovation powerhouse.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Topics to be discussed include an overview of our robust product pipeline with a focus on our exciting epcoritamab, tisotumab vedotin and DuoBody-PD-L1x4-1BB programs, a deep dive into our proprietary DuoBody technology and a look at how we are growing our capabilities across the company.